Proteasome inhibitors in cancer therapy: Treatment regimen and peripheral neuropathy as a side effect

Kaplan G. S. , Torcun C. C. , Grune T., Ozer N. , KARADEMİR B.

FREE RADICAL BIOLOGY AND MEDICINE, cilt.103, ss.1-13, 2017 (SCI İndekslerine Giren Dergi) identifier identifier identifier


Proteasomal system plays an important role in protein turnover, which is essential for homeostasis of cells. Besides degradation of oxidized proteins, it is involved in the regulation of many different signaling pathways. These pathways include mainly cell differentiation, proliferation, apoptosis, transcriptional activation and angiogenesis. Thus, proteasomal system is a crucial target for treatment of several diseases including neurodegenerative diseases, cystic fibrosis, atherosclerosis, autoimmune diseases, diabetes and cancer. Over the last fifteen years, proteasome inhibitors have been tested to highlight their mechanisms of action and used in the clinic to treat different types of cancer. Proteasome inhibitors are mainly used in combinational therapy along with classical chemo-radiotherapy. Several studies have proved their significant effects but serious side effects such as peripheral neuropathy, limits their use in required effective doses.